Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04245722
Title FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fate Therapeutics

B-cell lymphoma

chronic lymphocytic leukemia


Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab

Cyclophosphamide + Fludarabine + FT596

Cyclophosphamide + Fludarabine + FT596 + Rituximab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.